The challenge of managing XXXX .

@entity1 @entity1261 @entity2379 @entity281 @entity364 @entity5074 @entity22214 @entity3 @entity7143 @entity2841
Fusarium is the second most frequent mold involved in @entity364 and is particularly important among immunocompromised @entity1 . Culture methods and microscopy are still routinely used in clinical laboratories to identify Fusarium spp, and more sophisticated, timely, and effective methods for detecting Fusarium spp. in laboratory samples could improve the outcome of the @entity1 . These investigational diagnostic approaches include serological assays and specific nested PCR assays that can yield positive and negative predictive values of over 90%. Other assays in development, such as mass spectroscopy techniques, can provide accurate and consistent results. The treatment of @entity22214 in immunocompromised @entity1 remains a challenge and the prognosis of systemic @entity22214 in this population remains poor. Successful treatment is highly dependent on the particular Fusarium species involved in the @entity281 . High dose intravenous @entity2379 formulation is recommended as the first line of therapy in management of @entity22214 in @entity1 . @entity5074 is also effective in treating @entity22214 . Intolerance, contraindication, or failure of the @entity2379 formulation warrants the use of @entity5074 as an alternative agent, and @entity7143 is licensed as salvage therapy against @entity3 . Adjunctive therapies such as surgical debridement of infected tissue, @entity1261 ( @entity1261 ) or @entity2841 ( @entity2841 ) infusions, or granulocyte transfusions are also tools for managing @entity22214 . In conclusion, Fusarium @entity281 is considered an emerging problem and should be suspected in immunocompromised @entity1 experiencing @entity281 and should be treated accordingly.
